A FOURTH coronavirus vaccine could be approved in the UK within a matter of weeks as late-stage trials suggested it was 89 per cent effective in preventing the virus.
The UK has secured 60 million doses of the Novavax jab – to be produced on Teesside – which is believed to offer protection against the new UK and South African variants.
It was shown to be 89.3 per cent effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK, which involved more than 15,000 people aged between 18-84, of which 27 per cent were older than 65, Novavax said.
The vaccine will now be assessed by the Medicines and Healthcare products Regulatory Agency (MHRA), prime minister Boris Johnson confirmed, as he thanked volunteers who made the results possible.
MORE NEWS:
- Bundles Baby Clothing Bank helped in coronavirus pandemic
- 120mph racing drivers in near death duel on M4 in Newport
- Popular half marathon in aid of hospice goes virtual for 2021
Good news that the @Novavax vaccine has proved effective in UK trials. Thank you to all the volunteers who made these results possible.
— Boris Johnson (@BorisJohnson) January 28, 2021
Our medicines regulator will now assess the vaccine, which will be made in Teesside. If approved, we have 60m doses on order.
Stan Erck, chief executive of Novavax, told the BBC the manufacturing plant in Stockton-on-Tees should be up and running by March or April, with the company hoping to get approval for the vaccine from the MHRA around the same time.
Health secretary Matt Hancock said the NHS stands ready to roll out the vaccine if it is approved, which he said would provide a “significant boost to our vaccination programme and another weapon in our arsenal to beat this awful virus”.
The jab has shown around 60 per cent effectiveness against the South African variant, which has been worrying scientists due to concerns vaccines may not work against it, but it offered 86 per cent protection against the new UK strain.
Two vaccines have already been rolled out in the UK – from Pfizer and Oxford/AstraZeneca – while a third from Moderna has been approved for use.
How does it work?
The Novavax vaccine works like other vaccines by teaching the immune system to make antibodies to the coronavirus spike protein.
Researchers inserted a modified gene into a virus, called a baculovirus, and allowed it to infect insect cells.
Spike proteins from these cells were then assembled into nanoparticles which, while they look like coronavirus, cannot replicate or cause Covid-19.
These nanoparticles are then injected into the body via the vaccine where the immune system mounts an antibody response.
If the body encounters coronavirus in the future, the body is primed to fend it off.
How does it differ to other vaccines?
While the jabs from Pfizer/BioNTech and Moderna need to be kept at ultra-low temperatures, the Novavax jab is stable for up to three months in a normal fridge.
The jab should be available in the second half of this year and is being manufactured in Teeside.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here